Inhibiting cancer-causing protein could prevent scleroderma fibrosis

February 26, 2019

ANN ARBOR, Mich. - A protein known to play a role in cancer may also be increasing fibrosis in scleroderma patients.

Scleroderma, a rare, chronic autoimmune disease, is marked by hardening of the skin and internal organs. Symptoms often include pain, stiffness, fatigue and breathing difficulties.

"The disease creates excessive fibroblast activation that ultimately results in tissue damage and organ failure," says Amr Sawalha, M.D., a professor in the Division of Rheumatology at the University of Michigan.

In a new study, published in Proceedings of the National Academy of Sciences, Sawalha and his team examined scleroderma at the molecular level to better understand the fibrosis process.

"We examined the molecule EZH2, which has been known to play a role in several types of cancer," Sawalha says. "This protein regulates gene expression, by affecting modifications that happen to DNA and other proteins attached to DNA, through a process called epigenetic regulation."

Sawalha and fellow researchers had previously identified a role for EZH2 in lupus, another autoimmune disease, flares.

"EZH2 is overexpressed in lupus T cells, which makes these white blood cells active in lupus patients," he says. "We then expanded our studies to scleroderma and specifically looked at the role of EZH2 in fibroblasts and endothelial cells in this disease."

Examining EZH2

The research team first isolated cells from scleroderma patients in collaboration with the Michigan Medicine Scleroderma Program. The program provides care for a large number of scleroderma patients at the University of Michigan. They then expanded their studies to animal models to further test findings identified in the human cells.

"Both increased fibrosis and abnormal blood vessel function, or defective angiogenesis, are major aspects of pathology in this autoimmune disease," says Eliza Tsou, Ph.D., a research assistant professor at U-M and first author of the study. "We dissected the cells and found that increased levels of EZH2 were contributing to this disease process in scleroderma patients."

After identifying the molecule, the research team examined what happened in the cells when EZH2 was inhibited.

"When we suppressed EZH2, we found we could correct increased fibrosis and abnormal blood vessel function in scleroderma," Sawalha says.

Translating to the bedside

Because EZH2 is a molecule known to play a role in cancer patients, Sawalha says the ability to translate their laboratory work to patients may be easier.

"What is nice is that EZH2 inhibitors are already developed and in clinical trials in certain cancers," he says. "Therefore, our findings can be more readily translated to the bedside by repurposing already existing inhibitors for EZH2 to treat scleroderma."

As there are currently no effective treatment options for scleroderma, Sawalha notes that this type of research is important for future studies and trials.

"We will continue to research this disease at the molecular level and try to identify additional therapeutic targets for this patient population," he says.

Michigan Medicine - University of Michigan

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to